Arrowsmith

Arrowsmith Genetics Inc. is a preclinical-stage precision oncology company that reverse-engineers the drug development process to identify novel cancer therapeutic targets using a genetics-driven platform. Co-founded in 2021 by Peter Stirling (CEO), Nigel O'Neil (CSO), and Phil Hieter at the University of British Columbia, the company develops advanced cell-based drug models that reduce the risk and cost of early-stage cancer drug discovery — addressing the high failure rate of conventional target identification tools. Arrowsmith Genetics won the 2022 Amgen/SBME Golden Ticket award, advanced to the Top 25 of the NVBC Competition, and was selected as a UBC spin-off in 2024/2025, with an ambition to expand its pipeline of drug candidates across multiple tumor types for pharma partnerships.